Elekta AB (publ) (OTCMKTS:EKTAY) Posts Earnings Results

Elekta AB (publ) (OTCMKTS:EKTAY) announced its earnings results on Friday. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01), Zacks reports. Elekta AB (publ) had a return on equity of 11.07% and a net margin of 5.65%.

Elekta AB (publ) Stock Performance

Shares of OTCMKTS:EKTAY traded up $0.03 on Friday, reaching $6.09. 1,474 shares of the company’s stock were exchanged, compared to its average volume of 4,729. The company has a fifty day moving average of $5.72 and a 200-day moving average of $6.09. Elekta AB has a twelve month low of $5.25 and a twelve month high of $8.24. The company has a market capitalization of $2.34 billion, a price-to-earnings ratio of 24.36 and a beta of 1.22. The company has a current ratio of 1.05, a quick ratio of 0.81 and a debt-to-equity ratio of 0.60.

Elekta AB (publ) Cuts Dividend

The firm also recently announced a dividend, which will be paid on Thursday, March 27th. Shareholders of record on Friday, March 7th will be given a dividend of $0.1072 per share. The ex-dividend date is Friday, March 7th. Elekta AB (publ)’s payout ratio is presently 48.00%.

Wall Street Analyst Weigh In

Separately, Sanford C. Bernstein upgraded shares of Elekta AB (publ) from a “strong sell” rating to a “hold” rating in a research report on Wednesday, January 29th.

Elekta AB (publ) Company Profile

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services.